Antihemophilic factor
Antihemophilic factor is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Adynovate, Afstyla, Altuviiio, Eloctate, Esperoct, Hemofil m, Jivi, Koate, koate-dvi, Kovaltry, Obizur (discontinued: Monoclate, monoclate-p)
CombinationsAdvate, Alphanate, Humate-p, Xyntha, xyntha solofuse
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Antihemophilic factor
+
Von willebrand factor complex (human)
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Humate-P | Antihemophilic Factor/von Willebrand Factor Complex (Human) | CSL Behring | A-103960 RX | 2000-04-11 | 3 products |
| Alphanate | Antihemophilic Factor/von Willebrand Factor Complex (Human) | Grifols | A-102475 RX | 1978-08-15 | 5 products |
Antihemophilic factor (human)
Albumin free method
+
Antihemophilic factor (recombinant)
+
plasma
Albumin free
+
Antihemophilic factor (recombinant)
+
plasma
Antihemophilic factor (recombinant)
+
fc fusion protein
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Eloctate | Antihemophilic Factor (Recombinant), Fc Fusion protein | Bioverativ | A-125487 RX | 2014-06-06 | 10 products |
Antihemophilic factor (recombinant)
+
porcine sequence
Antihemophilic factor (recombinant)
+
pegylated
Antihemophilic factor (recombinant)
+
full length
Antihemophilic factor (recombinant)
+
single chain
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Afstyla | Antihemophilic Factor (Recombinant), Single Chain | CSL Behring | A-125591 RX | 2016-05-25 | 7 products |
Antihemophilic factor (recombinant)
+
glycopegylated
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Esperoct | Antihemophilic Factor (Recombinant), GlycoPEGylated-exei | Novo Nordisk | A-125671 RX | 2019-02-19 | 5 products |
Antihemophilic factor (recombinant)
+
fc-vwf-xten fusion protein
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| ALTUVIIIO | antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl | Bioverativ | N-125771 RX | 2023-02-22 | 7 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| alphanate | Biologic Licensing Application | 2010-10-07 |
| altuviiio | Biologic Licensing Application | 2024-09-05 |
| hemofil m | Biologic Licensing Application | 2011-03-15 |
| humate-p | Biologic Licensing Application | 2010-01-14 |
| recombinate | Export only | 2010-05-26 |
| von willebrand factor/coagulation factor viii complex (human) | Biologic Licensing Application | 2010-08-20 |
| xyntha | Biologic Licensing Application | 2010-08-31 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7180 | Injection, factor xiii (antihemophilic factor, human), 1 i.u. |
| J7182 | Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu |
| J7185 | Injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u. |
| J7186 | Injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u. |
| J7188 | Injection, factor viii (antihemophilic factor, recombinant), (obizur), per i.u. |
| J7189 | Factor viia (antihemophilic factor, recombinant), (novoseven rt), 1 microgram |
| J7190 | Factor viii (antihemophilic factor, human) per i.u. |
| J7191 | Factor viii (antihemophilic factor (porcine)), per i.u. |
| J7192 | Factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified |
| J7193 | Factor ix (antihemophilic factor, purified, non-recombinant) per i.u. |
Show 10 more
Clinical
Clinical Trials
509 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia a | D006467 | EFO_0007267 | D66 | 65 | 58 | 125 | 64 | 177 | 456 |
| Hemophilia b | D002836 | — | D67 | 8 | 8 | 17 | 3 | 24 | 55 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 6 | 2 | 7 | 3 | 13 | 29 |
| Hemostatic disorders | D020141 | — | — | 6 | 2 | 7 | 3 | 13 | 29 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | 2 | 3 | 13 | 4 | 4 | 25 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 4 | 4 | 8 | 16 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 2 | 2 | 1 | 2 | 3 | 8 |
| Inherited blood coagulation disorders | D025861 | — | — | 1 | 1 | — | 1 | 3 | 5 |
| Joint diseases | D007592 | HP_0003040 | M12.9 | — | — | — | 1 | 4 | 5 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | 1 | 1 | 1 | 4 |
Show 12 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic disorders | D006474 | — | D69.9 | 1 | 1 | 1 | — | 3 | 5 |
| Deficiency diseases | D003677 | EFO_1001067 | E63 | — | — | 1 | — | 1 | 2 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | 1 | — | 1 | — | — | 2 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | 1 | — | — | 2 |
| Bone diseases | D001847 | — | M89.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | 1 | — | — | — | 5 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | 3 | 4 |
| Coagulation protein disorders | D020147 | — | — | 1 | 1 | — | — | 2 | 3 |
| Genetic therapy | D015316 | — | — | 2 | 2 | — | — | 1 | 3 |
| Inborn genetic diseases | D030342 | EFO_0000508 | — | 1 | 1 | — | — | 1 | 2 |
| X-linked genetic diseases | D040181 | — | — | 1 | 1 | — | — | 1 | 2 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | — | — | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | — | 1 | — | — | — | 1 |
| Dependovirus | D000229 | — | — | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 3 von willebrand disease | D056729 | Orphanet_166096 | D68.03 | 2 | — | — | — | 1 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Factor vii deficiency | D005168 | HP_0008169 | D68.2 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | — | — | 3 | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 2 | 2 |
| Infertility | D007246 | HP_0000789 | — | — | — | — | — | 2 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Seroma | D049291 | — | — | — | — | — | — | 1 | 1 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | — | — | 1 | 1 |
| Replacement arthroplasty | D019643 | — | — | — | — | — | — | 1 | 1 |
| Hemolysis | D006461 | — | — | — | — | — | — | 1 | 1 |
| Hemolytic anemia | D000743 | — | D55-D59 | — | — | — | — | 1 | 1 |
| Postmenopause | D017698 | — | — | — | — | — | — | 1 | 1 |
Show 47 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Antihemophilic factor |
| INN | — |
| Description | Alphanate (antihemophilic factor) is a protein pharmaceutical. It is a lyophilized concentrate of Factor VIII (FVIII; AHF) and von Willebrand Factor (VWF). |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >4KI5:C|MURINE MONOCLONAL 3E6 FAB HEAVY CHAIN
QIQLVQSGPELKKPGKTVKISCKASDYTFTDYSLHWVKQAPGKGLKWMGWINTETGDPAYADDFKGRFAFSLETSVRTAY
LQINNLKNEDTAIYFCAREDDGLASWGQGTTLTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSG
SLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPA
>4KI5:D|MURINE MONOCLONAL 3E6 FAB LIGHT CHAIN
QIVLTQSPAIMSASPGEKVTMTCSASSTVSYMYWYQQKPGSSPRFLISDTSNLASGVPVRFSGSGSGTSYSLTISRIEAE
DAATYYCQHWSSYPLTFGGGTKLELKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLN
SWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>4KI5:E|MURINE MONOCLONAL G99 FAB HEAVY CHAIN
QVQLQQSGAELMKPGASVKISCKATGYTFSSYWIEWVKQRPGHGLEWIGEILPGSGSTNYNERFKGKASFTADSSSNTAY
MQLSSLTSEDSAVYYCTRTSYYFGSSYDFDVWGAGTTVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVT
LTWNSGSLSSGVHTFPALLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGP
>4KI5:F|MURINE MONOCLONAL G99 FAB LIGHT CHAIN
DIQMTQSPSSLSASLGERVSLTCRASQEISGYLSWLQQKPDGTIKRLIYAASTLDSSVPKRFSGSRSGSDYSLTISSLDS
EDFAVYYCLQYASYPYTFGGGTKVEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVL
NSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC
>4KI5:M|Coagulation factor VIII
MGSSHHHHHHSSGLVPRGSHMLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEW
LQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIH
PQSWVHQIALRMEVLGCEAQDLY |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Antihemophilic factor
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,578 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,890 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use